Purpose: To describe the management with intracameral recombinant tissue plasminogen activator (rtPA) of severe fibrin effusion after phacoemulsification, and its prevention with sustained-release dexamethasone intravitreal implant. Methods: A 59-year-old man with chronic HLA-B27-associated uveitis underwent phacoemulsification followed by a sustained-release dexamethasone intravitreal implant. Results: A postoperative severe fibrin reaction was completely resolved after intracameral injection of rtPA. At the time of the phacoemulsification of the fellow eye, a dexamethasone implant was injected 5 days prior to surgery, with no fibrin formation. Conclusions: Intracameral rtPA may be successfully used in the management of severe fibrin reaction. Dexamethasone intravitreal implant to control postoperative inflammation may take several days until it achieves high concentrations in the vitreous.

Fibrin reaction after uveitic cataract surgery : treatment and prevention / B. da Rocha Lima, F. Pichi, P. Nucci, S.K. Srivastava, C.Y. Lowder. - In: EUROPEAN JOURNAL OF OPHTHALMOLOGY. - ISSN 1120-6721. - 24:4(2014 Jul), pp. 626-628. [10.5301/ejo.5000442]

Fibrin reaction after uveitic cataract surgery : treatment and prevention

F. Pichi
Secondo
;
P. Nucci;
2014

Abstract

Purpose: To describe the management with intracameral recombinant tissue plasminogen activator (rtPA) of severe fibrin effusion after phacoemulsification, and its prevention with sustained-release dexamethasone intravitreal implant. Methods: A 59-year-old man with chronic HLA-B27-associated uveitis underwent phacoemulsification followed by a sustained-release dexamethasone intravitreal implant. Results: A postoperative severe fibrin reaction was completely resolved after intracameral injection of rtPA. At the time of the phacoemulsification of the fellow eye, a dexamethasone implant was injected 5 days prior to surgery, with no fibrin formation. Conclusions: Intracameral rtPA may be successfully used in the management of severe fibrin reaction. Dexamethasone intravitreal implant to control postoperative inflammation may take several days until it achieves high concentrations in the vitreous.
intracameral recombinant tissue plasminogen activator; postsurgical fibrin reaction; sustained-release dexamethasone intravitreal implant; dexamethasone; drug implants; fibrin; fibrinolytic agents; glucocorticoids; HLA-B27 antigen; humans; male; middle aged; tissue plasminogen activator; uveitis; phacoemulsification; ophthalmology
Settore MED/30 - Malattie Apparato Visivo
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/246658
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact